CD19 and diffuse large B-cell lymphoma: Notably, multiomic analyses of the DLBCL tumor microenvironment have revealed that immune gene expression profiles and cell-of-origin classifications are significantly correlated with the clinical response to mosunetuzumab, but not to CD19-directed CAR T-cell therapies [42], indicating a potentially distinct pattern of responsiveness based on the immune milieu.